Search Results - "LAHUERTA, J"

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma by Flores-Montero, J, Sanoja-Flores, L, Paiva, B, Puig, N, García-Sánchez, O, Böttcher, S, van der Velden, V H J, Pérez-Morán, J-J, Vidriales, M-B, García-Sanz, R, Jimenez, C, González, M, Martínez-López, J, Corral-Mateos, A, Grigore, G-E, Fluxá, R, Pontes, R, Caetano, J, Sedek, L, del Cañizo, M-C, Bladé, J, Lahuerta, J-J, Aguilar, C, Bárez, A, García-Mateo, A, Labrador, J, Leoz, P, Aguilera-Sanz, C, San-Miguel, J, Mateos, M-V, Durie, B, van Dongen, J J M, Orfao, A

“…Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow…”
Get full text

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study by Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, Durie, B G M

“…Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this…”
Get full text

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway by Smith, Alison E., Ferraro, Emanuela, Safonov, Anton, Morales, Cristina Bernado, Lahuerta, Enrique J. Arenas, Li, Qing, Kulick, Amanda, Ross, Dara, Solit, David B., de Stanchina, Elisa, Reis-Filho, Jorge, Rosen, Neal, Arribas, Joaquín, Razavi, Pedram, Chandarlapaty, Sarat

“…Inhibition of HER2 in HER2-amplified breast cancer has been remarkably successful clinically, as demonstrated by the efficacy of HER-kinase inhibitors and…”
Get full text

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential by Paíno, T, Paiva, B, Sayagués, J M, Mota, I, Carvalheiro, T, Corchete, L A, Aires-Mejía, I, Pérez, J J, Sanchez, M L, Barcena, P, Ocio, E M, San-Segundo, L, Sarasquete, M E, García-Sanz, R, Vidriales, M-B, Oriol, A, Hernández, M-T, Echeveste, M-A, Paiva, A, Blade, J, Lahuerta, J-J, Orfao, A, Mateos, M-V, Gutiérrez, N C, San-Miguel, J F

“…Knowledge about clonal diversity and selection is critical to understand multiple myeloma (MM) pathogenesis, chemoresistance and progression. If targeted…”
Get full text

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma by Martinez-Lopez, Joaquin, Lahuerta, Juan J., Pepin, François, González, Marcos, Barrio, Santiago, Ayala, Rosa, Puig, Noemí, Montalban, María A., Paiva, Bruno, Weng, Li, Jiménez, Cristina, Sopena, María, Moorhead, Martin, Cedena, Teresa, Rapado, Immaculada, Mateos, María Victoria, Rosiñol, Laura, Oriol, Albert, Blanchard, María J., Martínez, Rafael, Bladé, Joan, San Miguel, Jesús, Faham, Malek, García-Sanz, Ramón

“…We assessed the prognostic value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using a sequencing-based platform in bone marrow…”
Get full text

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control by Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, Miguel, J F San

“…Achieving complete remission (CR) in multiple myeloma (MM) translates into extended survival, but two subgroups of patients fall outside this paradigm: cases…”
Get full text

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) by Ocio, E M, Richardson, P G, Rajkumar, S V, Palumbo, A, Mateos, M V, Orlowski, R, Kumar, S, Usmani, S, Roodman, D, Niesvizky, R, Einsele, H, Anderson, K C, Dimopoulos, M A, Avet-Loiseau, H, Mellqvist, U-H, Turesson, I, Merlini, G, Schots, R, McCarthy, P, Bergsagel, L, Chim, C S, Lahuerta, J J, Shah, J, Reiman, A, Mikhael, J, Zweegman, S, Lonial, S, Comenzo, R, Chng, W J, Moreau, P, Sonneveld, P, Ludwig, H, Durie, B G M, Miguel, J F S

“…Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs…”
Get full text

Management of treatment-emergent peripheral neuropathy in multiple myeloma by Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, Sonneveld, P

“…Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects…”
Get full text

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials by Arana, P, Paiva, B, Cedena, M-T, Puig, N, Cordon, L, Vidriales, M-B, Gutierrez, N C, Chiodi, F, Burgos, L, Anglada, L-L, Martinez-Lopez, J, Hernandez, M-T, Teruel, A-I, Gironella, M, Echeveste, M-A, Rosiñol, L, Martinez, R, Oriol, A, De la Rubia, J, Orfao, A, Blade, J, Lahuerta, J-J, Mateos, M-V, San Miguel, J-F

“…Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great…”
Get full text

International Staging System for Multiple Myeloma by GREIPP, Philip R, SAN MIGUEL, Jesus, LAHUERTA, Juan J, LUDWIG, Heinz, MORGAN, Gareth, POWLES, Raymond, SHIMIZU, Kazuyuki, SHUSTIK, Chaim, SONNEVELD, Pieter, TOSI, Patrizia, TURESSON, Ingemar, WESTIN, Jan, DURIE, Brian G. M, CROWLEY, John J, BARLOGIE, Bart, BLADE, Joan, BOCCADORO, Mario, CHILD, J. Anthony, HAROUSSEAU, Jean-Luc, KYLE, Robert A

“…There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification…”
Get full text

Differentiation stage of myeloma plasma cells: biological and clinical significance by Paiva, B, Puig, N, Cedena, M T, de Jong, B G, Ruiz, Y, Rapado, I, Martinez-Lopez, J, Cordon, L, Alignani, D, Delgado, J A, van Zelm, M C, Van Dongen, J J M, Pascual, M, Agirre, X, Prosper, F, Martín-Subero, J I, Vidriales, M-B, Gutierrez, N C, Hernandez, M T, Oriol, A, Echeveste, M A, Gonzalez, Y, Johnson, S K, Epstein, J, Barlogie, B, Morgan, G J, Orfao, A, Blade, J, Mateos, M V, Lahuerta, J J, San-Miguel, J F

“…The notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity…”
Get full text

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project by Avet-Loiseau, H, Durie, B G M, Cavo, M, Attal, M, Gutierrez, N, Haessler, J, Goldschmidt, H, Hajek, R, Lee, J H, Sezer, O, Barlogie, B, Crowley, J, Fonseca, R, Testoni, N, Ross, F, Rajkumar, S V, Sonneveld, P, Lahuerta, J, Moreau, P, Morgan, G

“…The combination of serum β2-microglobulin and albumin levels has been shown to be highly prognostic in myeloma as the International Staging System (ISS). The…”
Get full text

Second primary malignancies in multiple myeloma: an overview and IMWG consensus by Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., Palumbo, A.

“…Therapeutic advancements following the introduction of autologous stem cell transplantation and ‘novel’ agents have significantly improved clinical outcomes…”
Get full text

Diaphragmatic paralysis, respiratory function, and postoperative pain after interscalene brachial plexus block with a reduced dose of 10 ml levobupivacaine 0.25% versus a 20 ml dose in patients undergoing arthroscopic shoulder surgery: study protocol for the randomized controlled double-blind REDOLEV study by Oliver-Fornies, P, Ortega Lahuerta, J P, Gomez Gomez, R, Gonzalo Pellicer, I, Oliden Gutierrez, L, Viñuales Cabeza, J, Gallego Ligorit, L, Orellana Melgar, C E

“…Arthroscopic shoulder surgery causes severe postoperative pain. An interscalene brachial plexus block provides adequate analgesia, but unintended spread of the…”
Get full text

Ramsey interferometry with generalized one-axis twisting echoes by Schulte, Marius, Martínez-Lahuerta, Victor J., Scharnagl, Maja S., Hammerer, Klemens

“…We consider a large class of Ramsey interferometry protocols which are enhanced by squeezing and un-squeezing operations before and after a phase signal is…”
Get full text

A randomised controlled trial in patients undergoing arthroscopic shoulder surgery comparing interscalene block with either 10 ml or 20 ml levobupivacaine 0.25 by Oliver‐Fornies, P., Gomez Gomez, R., Ortega Lahuerta, J. P., Carbonel Bueno, I., Gonzalo Pellicer, I., Ripalda Marin, J., Orellana Melgar, C. E., Fajardo Perez, M.

“…Summary The interscalene brachial plexus block is recommended for analgesia after shoulder surgery but it may cause hemidiaphragmatic dysfunction. We tested…”
Get full text

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry by Puig, N, Sarasquete, M E, Balanzategui, A, Martínez, J, Paiva, B, García, H, Fumero, S, Jiménez, C, Alcoceba, M, Chillón, M C, Sebastián, E, Marín, L, Montalbán, M A, Mateos, M V, Oriol, A, Palomera, L, de la Rubia, J, Vidriales, M B, Bladé, J, Lahuerta, J J, González, M, Miguel, J F S, García-Sanz, R

“…We have analyzed the applicability, sensitivity and prognostic value of allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) as a method for…”
Get full text

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression by Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., Gonzalez-Calle, V., Rodriguez-Otero, P., Oriol, A., Rosiñol, L., Alegre, A., Escalante, F., De La Rubia, J., Teruel, A. I., De Arriba, F., Hernandez, M. T., Lopez-Jimenez, J., Ocio, E. M., Puig, N., Paiva, B., Lahuerta, J. J., Bladé, J., San Miguel, J. F., Mateos, M. V., Martinez-Lopez, J., Calasanz, M. J., Garcia-Sanz, R.

“…Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk…”
Get full text

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma by Paiva, B, Pérez-Andrés, M, Vídriales, M-B, Almeida, J, de las Heras, N, Mateos, M-V, López-Corral, L, Gutiérrez, N C, Blanco, J, Oriol, A, Hernández, M T, de Arriba, F, de Coca, A G, Terol, M-J, de la Rubia, J, González, Y, Martín, A, Sureda, A, Schmidt-Hieber, M, Schmitz, A, Johnsen, H E, Lahuerta, J-J, Bladé, J, San-Miguel, J F, Orfao, A

“…Disappearance of normal bone marrow (BM) plasma cells (PC) predicts malignant transformation of monoclonal gammopathy of undetermined significance (MGUS) and…”
Get full text

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients by Paiva, B, Gutiérrez, N-C, Chen, X, Vídriales, M-B, Montalbán, M-Á, Rosiñol, L, Oriol, A, Martínez-López, J, Mateos, M-V, López-Corral, L, Díaz-Rodríguez, E, Pérez, J-J, Fernández-Redondo, E, de Arriba, F, Palomera, L, Bengoechea, E, Terol, M-J, de Paz, R, Martin, A, Hernández, J, Orfao, A, Lahuerta, J-J, Bladé, J, Pandiella, A, Miguel, J-F San

“…The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated…”
Get full text